摘要
目的比较卡维地洛.美托洛尔长期治疗老年慢性心力衰竭(CHF)的疗效。方法将82例NYHA心功能Ⅱ～Ⅳ级CHF老年患者随机分为两组:卡维地洛组40例,采用常规治疗(ACEI、利尿剂、血管扩张剂、洋地黄)+卡维地洛;美托洛尔组42例,采用常规治疗+美托洛尔。治疗12个月,观察两组治疗后左室舒张末期内径(LVEDD),左室收缩末期内径(LVESD)、左室射血分数(LVEF)及心功能变化。结果两组治疗后LVEDD、LVESD、LVEF、心功能改善均较治疗前有显著改善(P<0.01);而卡维地洛组在LVEDD、LVESD、LVEF方面的改善上较美托洛尔组更明显(P<0.01),在心功能改善方面较美托洛尔组差异有统计学意义(P<0.05)。两组均无不良反应发生。结论长期应用卡维地洛治疗老年CHF的疗效优于美托洛尔。
Objective This study was performed tO compare the long-term clinical efficacy of treatment with metoprolol versus carvedilol in elderly patients with chronic heart failure. Methods 82 patients with chronic congestive heart failure requiring diuretic therapy and with left ventricular dysfunction （ NYHA Ⅱ-Ⅳ ） were randomized to treatment with carvediol （ n = 40 ） or metoprolol （ n = 42 ）. The two groups both were given to standard therapy （ACEI,diuretic, sodium nitroprusside, digitoxin）in addition to carvedilol of metoprolol. One year after the previous treatment, response was assessed by LVEDD, LVESD, LV ejection fraction and New York Heart Association class. Results A year after the previous treatment, both carvedilol and metolprolol produced highly significant improvement in LVEF,LVEDD,LVESD as well as LV ejection fraction, and New York Heart Association functional class. Compared with metoprolol, Carvedilol had a significantly greater effect on LV end-diastolic dimension, LVESD and LV ejection （ P 〈 0.01 ）, however, on New York Heart Association functional class （ P 〈 0.05 ）. Conclusion Compared with metoprolol, long-term treatment with Carvedilol can gain more benefit in-elderly patients with chronic heart failure.
出处
《四川医学》
CAS
2008年第5期517-518,共2页
Sichuan Medical Journal
